Rite Aid Reports Fiscal 2017 Second Quarter Results

CAMP HILL, Pa.--(BUSINESS WIRE)--

Rite Aid Corporation RAD today reported operating results for its second fiscal quarter ended August 27, 2016.

For the second quarter, the company reported revenues of $8.0 billion, net income of $14.8 million, or $0.01 per diluted share, Adjusted net income of $35.5 million, or $0.03 per diluted share and Adjusted EBITDA of $312.7 million, or 3.9 percent of revenues.

"In the second quarter, we continued to drive positive results in our Pharmacy Services Segment, which includes our EnvisionRx PBM, and had strong performance in our front-end business," said Chairman and CEO John Standley. "We also saw improvements in prescription drug costs, but these improvements were more than offset by the challenging reimbursement rate environment, which we expect to continue through the remainder of the fiscal year. Heading forward, we will remain focused on operating our business as efficiently as possible while pursuing key growth opportunities such as our flu immunization campaign and converting additional stores to the Wellness format, which continue to perform well and now represent nearly half of our chain."

Second Quarter Summary

Revenues for the quarter were $8.0 billion compared to revenues of $7.7 billion in the prior year's second quarter, an increase of $365.0 million or 4.8 percent. Retail Pharmacy Segment revenues were $6.5 billion and decreased 2.4 percent compared to the prior year period primarily as a result of a decrease in same store sales. Revenues in the company's Pharmacy Services Segment, which was acquired on June 24, 2015, were $1.6 billion.

Same store sales for the quarter decreased 2.5 percent over the prior year, consisting of a 3.6 percent decrease in pharmacy sales, partially offset by a 0.1 percent increase in front-end sales. Pharmacy sales included an approximate 101 basis point negative impact from new generic introductions. The number of prescriptions filled in same stores decreased 1.8 percent over the prior year period. Prescription sales accounted for 68.5 percent of total drugstore sales, and third party prescription revenue was 98.1 percent of pharmacy sales.

Net income was $14.8 million or $0.01 per diluted share compared to last year's second quarter net income of $21.5 million or $0.02 per diluted share. The decline in operating results is due primarily to a higher LIFO charge, and a decline in Adjusted net income, partially offset by a $33.2 million loss on debt retirement in the prior year related to the redemption of the company's 8.00% senior secured notes.

Adjusted net income and Adjusted net income per diluted share (which is reconciled to net income on the attached table) was $35.5 million or $0.03 per diluted share compared to last year's second quarter Adjusted net income of $58.7 million or $0.06 per diluted share. The decline in Adjusted net income and Adjusted net income per share is due to a decrease in Adjusted EBITDA, partially offset by lower income tax and interest expenses.

Adjusted EBITDA (which is reconciled to net income on the attached table) was $312.7 million or 3.9 percent of revenues for the second quarter compared to $346.8 million or 4.5 percent of revenues for the same period last year. The decline in Adjusted EBITDA is due to a decrease of $51.0 million in the Retail Pharmacy Segment, resulting from lower gross profit and higher SG&A expense. Gross profit declined due to lower pharmacy gross profit partially offset by an increase in front end gross profit. Pharmacy gross profit decreased because of lower reimbursement rates and script count, partially offset by improvements in prescription drug costs. SG&A expense increased due to a shift in the timing of Memorial Day holiday pay and increased benefit costs. The decline in Retail Pharmacy Segment Adjusted EBITDA was partially offset by an increase of $16.8 million of Pharmacy Services Segment Adjusted EBITDA. This increase was due to strong operating results in the current year and the fact that prior year's Pharmacy Services Segment results do not reflect a full quarter's ownership of Envision Rx.

In the second quarter, the company opened 3 stores, relocated 6 stores, and remodeled 85 stores, bringing the total number of wellness stores chainwide to 2,214. The company also acquired 1 store and closed 14 stores, resulting in a total store count of 4,550 at the end of the second quarter. The company also opened 10 clinics in the second quarter, bringing the total to 90.

As previously announced on October 27, 2015, Rite Aid and Walgreens Boots Alliance, Inc. ("WBA") entered into a definitive agreement under which WBA will acquire all outstanding shares of Rite Aid for $9.00 per share in cash. The board of directors of both companies and Rite Aid's shareholders have approved the transaction, which is subject to certain conditions, including, among others, the receipt of approval under applicable antitrust laws and other customary closing conditions. The company continues to believe that the transaction will close in the second half of calendar year 2016.

Rite Aid is one of the nation's leading drugstore chains with 4,550 stores in 31 states and the District of Columbia. Information about Rite Aid, including corporate background and press releases, is available through Rite Aid's website at www.riteaid.com.

Cautionary Statement Regarding Forward Looking Statements

Statements in this release that are not historical and statements regarding the expected timing of the closing of the proposed merger with WBA and the ability of the parties to complete such transaction considering the various closing conditions and any assumptions underlying any of the foregoing, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," and "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, our high level of indebtedness and our ability to make interest and principal payments on our debt and satisfy the other covenants contained in our debt agreements, general economic, market and competitive conditions, our ability to improve the operating performance of our stores in accordance with our long term strategy, the impact of private and public third-party payers continued reduction in prescription drug reimbursements and efforts to encourage mail order, our ability to manage expenses and our investments in working capital, outcomes of legal and regulatory matters, changes in legislation or regulations, including healthcare reform, our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs and risks related to the proposed merger. These and other risks, assumptions and uncertainties are more fully described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K, in the definitive proxy statement that we filed with the Securities and Exchange Commission on December 21, 2015 in connection with the proposed merger, and in other documents that we file or furnish with the Securities and Exchange Commission, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Additionally, there can be no assurance that the proposed merger will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the proposed merger will be realized. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Rite Aid expressly disclaims any current intention to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

Reconciliation of Non-GAAP Financial Measures

The company separately reports financial results on the basis of Adjusted Net Income, Adjusted Net Income per diluted share, and Adjusted EBITDA, which are non-GAAP financial measures. See the attached tables for a reconciliation of Adjusted Net Income, Adjusted Net Income per diluted share and Adjusted EBITDA to net income, and net income per diluted share, which are the most directly comparable GAAP financial measures. Adjusted Net Income and Adjusted Net Income per diluted share exclude amortization of EnvisionRx intangible assets, merger and acquisition-related costs, loss on debt retirements and LIFO adjustments. Adjusted EBITDA is defined as net income excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility closing and impairment, inventory write-downs related to store closings, debt retirements and other items (including stock-based compensation expense, merger and acquisition-related costs, severance and costs related to distribution center closures, gain or loss on sale of assets and revenue deferrals related to our customer loyalty program).

RITE AID CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands)
(unaudited)
		August 27, 2016				February 27, 2016
ASSETS
Current assets:
Cash and cash equivalents		$	136,093			$	124,471
Accounts receivable, net			1,828,641				1,601,008
Inventories, net of LIFO reserve of $1,033,907 and $1,006,396			2,827,018				2,697,104
Prepaid expenses and other current assets			146,764				128,144
Total current assets			4,938,516				4,550,727
Property, plant and equipment, net			2,281,392				2,255,398
Goodwill			1,715,479				1,713,475
Other intangibles, net			921,348				1,004,379
Deferred tax assets			1,538,604				1,539,141
Other assets			215,630				213,890
Total assets		$	11,610,969			$	11,277,010
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations		$	24,399			$	26,848
Accounts payable			1,695,840				1,542,797
Accrued salaries, wages and other current liabilities			1,331,707				1,427,250
Total current liabilities			3,051,946				2,996,895
Long-term debt, less current maturities			7,173,656				6,914,393
Lease financing obligations, less current maturities			46,641				52,895
Other noncurrent liabilities			722,057				731,399
Total liabilities			10,994,300				10,695,582
Commitments and contingencies			-				-
Stockholders' equity:
Common stock			1,052,125				1,047,754
Additional paid-in capital			4,841,988				4,822,665
Accumulated deficit			(5,231,025	)			(5,241,210	)
Accumulated other comprehensive loss			(46,419	)			(47,781	)
Total stockholders' equity			616,669				581,428
Total liabilities and stockholders' equity		$	11,610,969			$	11,277,010

RITE AID CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except per share amounts)
(unaudited)
		Thirteen weeks ended August 27, 2016			Thirteen weeks ended August 29, 2015
Revenues		$	8,029,806		$	7,664,776
Costs and expenses:
Cost of revenues			6,113,063			5,742,485
Selling, general and administrative expenses			1,778,247			1,725,826
Lease termination and impairment charges			7,233			9,637
Interest expense			105,388			115,410
Loss on debt retirements, net			-			33,205
Loss on sale of assets, net			174			281
			8,004,105			7,626,844
Income before income taxes			25,701			37,932
Income tax expense			10,928			16,463
Net income		$	14,773		$	21,469
Basic and diluted earnings per share:
Numerator for earnings per share:
Income attributable to common stockholders - basic and diluted		$	14,773		$	21,469
Denominator:
Basic weighted average shares			1,044,198			1,029,793
Outstanding options and restricted shares, net			17,251			19,341
Diluted weighted average shares			1,061,449			1,049,134
Basic and diluted income per share		$	0.01		$	0.02

RITE AID CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except per share amounts)
(unaudited)
		Twenty-six weeks ended August 27, 2016			Twenty-six weeks ended August 29, 2015
Revenues		$	16,213,987		$	14,312,337
Costs and expenses:
Cost of revenues			12,402,944			10,530,516
Selling, general and administrative expenses			3,571,494			3,425,411
Lease termination and impairment charges			13,014			14,659
Interest expense			210,501			239,017
Loss on debt retirements, net			-			33,205
Loss on sale of assets, net			1,230			320
			16,199,183			14,243,128
Income before income taxes			14,804			69,209
Income tax expense			4,619			28,904
Net income		$	10,185		$	40,305
Basic and diluted earnings per share:
Numerator for earnings per share:
Income attributable to common stockholders - basic and diluted		$	10,185		$	40,305
Denominator:
Basic weighted average shares			1,043,317			1,008,242
Outstanding options and restricted shares, net			17,210			18,959
Diluted weighted average shares			1,060,527			1,027,201
Basic and diluted income per share		$	0.01		$	0.04

RITE AID CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
(unaudited)
		Thirteen weeks ended August 27, 2016			Thirteen weeks ended August 29, 2015
Net income		$	14,773		$	21,469
Other comprehensive income:
Defined benefit pension plans:
Amortization of prior service cost, net transition obligation and net actuarial losses included in net periodic pension cost, net of $451 and $398 tax expense			681			598
Total other comprehensive income			681			598
Comprehensive income		$	15,454		$	22,067

RITE AID CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
(unaudited)
		Twenty-six weeks ended August 27, 2016			Twenty-six weeks ended August 29, 2015
Net income		$	10,185		$	40,305
Other comprehensive income:
Defined benefit pension plans:
Amortization of prior service cost, net transition obligation and net actuarial losses included in net periodic pension cost, net of $902 and $796 tax expense			1,362			1,195
Total other comprehensive income			1,362			1,195
Comprehensive income		$	11,547		$	41,500

RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL SEGMENT OPERATING INFORMATION
(Dollars in thousands)
(unaudited)
		Thirteen weeks ended August 27, 2016			Thirteen weeks ended August 29, 2015
Retail Pharmacy Segment
Revenues (a)		$	6,485,482		$	6,647,243
Cost of revenues (a)			4,666,133			4,786,730
Gross profit			1,819,349			1,860,513
LIFO charge			13,760			5,986
FIFO gross profit			1,833,109			1,866,499
Gross profit as a percentage of revenues			28.05%			27.99%
LIFO charge as a percentage of revenues			0.21%			0.09%
FIFO gross profit as a percentage of revenues			28.26%			28.08%
Selling, general and administrative expenses			1,708,633			1,678,909
Selling, general and administrative expenses as a percentage of revenues			26.35%			25.26%
Cash interest expense			100,105			109,796
Non-cash interest expense			5,273			5,608
Total interest expense			105,378			115,404
Adjusted EBITDA			262,643			313,602
Adjusted EBITDA as a percentage of revenues			4.05%			4.72%
Pharmacy Services Segment
Revenues (a)		$	1,634,876		$	1,071,889
Cost of revenues (a)			1,537,482			1,010,111
Gross profit			97,394			61,778
Gross profit as a percentage of revenues			5.96%			5.76%
Adjusted EBITDA			50,010			33,222
Adjusted EBITDA as a percentage of revenues			3.06%			3.10%

(a) -		Revenues and cost of revenues include $90,552 and $54,356 of inter-segment activity for the thirteen weeks ended August 27, 2016 and August 29, 2015, respectively, that is eliminated in consolidation.

RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL SEGMENT OPERATING INFORMATION
(Dollars in thousands)
(unaudited)
		Twenty-six weeks ended August 27, 2016			Twenty-six weeks ended August 29, 2015
Retail Pharmacy Segment
Revenues (a)		$	13,161,030		$	13,294,804
Cost of revenues (a)			9,536,314			9,574,761
Gross profit			3,624,716			3,720,043
LIFO charge			27,511			11,973
FIFO gross profit			3,652,227			3,732,016
Gross profit as a percentage of revenues			27.54%			27.98%
LIFO charge as a percentage of revenues			0.21%			0.09%
FIFO gross profit as a percentage of revenues			27.75%			28.07%
Selling, general and administrative expenses			3,432,536			3,378,494
Selling, general and administrative expenses as a percentage of revenues			26.08%			25.41%
Cash interest expense			199,787			212,558
Non-cash interest expense			10,702			26,453
Total interest expense			210,489			239,011
Adjusted EBITDA			507,470			612,865
Adjusted EBITDA as a percentage of revenues			3.86%			4.61%
Pharmacy Services Segment
Revenues (a)		$	3,237,235		$	1,071,889
Cost of revenues (a)			3,050,908			1,010,111
Gross profit			186,327			61,778
Gross profit as a percentage of revenues			5.76%			5.76%
Adjusted EBITDA			91,185			33,222
Adjusted EBITDA as a percentage of revenues			2.82%			3.10%

(a) -		Revenues and cost of revenues include $184,278 and $54,356 of inter-segment activity for the twenty-six weeks ended August 27, 2016 and August 29, 2015, respectively, that is eliminated in consolidation.

RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
(In thousands)
(unaudited)
		Thirteen weeks ended August 27, 2016			Thirteen weeks ended August 29, 2015
Reconciliation of net income to adjusted EBITDA:
Net income		$	14,773		$	21,469
Adjustments:
Interest expense			105,388			115,410
Income tax expense			10,928			16,463
Depreciation and amortization			142,051			127,699
LIFO charge			13,760			5,986
Lease termination and impairment charges			7,233			9,637
Loss on debt retirements, net			-			33,205
Other			18,520			16,955
Adjusted EBITDA		$	312,653		$	346,824
Percent of revenues			3.89%			4.52%

RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
(In thousands)
(unaudited)
		Twenty-six weeks ended August 27, 2016			Twenty-six weeks ended August 29, 2015
Reconciliation of net income to adjusted EBITDA:
Net income		$	10,185		$	40,305
Adjustments:
Interest expense			210,501			239,017
Income tax expense			4,619			28,904
Depreciation and amortization			280,839			237,348
LIFO charge			27,511			11,973
Lease termination and impairment charges			13,014			14,659
Loss on debt retirements, net			-			33,205
Other			51,986			40,676
Adjusted EBITDA		$	598,655		$	646,087
Percent of revenues			3.69%			4.51%

RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
ADJUSTED NET INCOME
(Dollars in thousands, except per share amounts)
(unaudited)
		Thirteen weeks ended August 27, 2016			Thirteen weeks ended August 29, 2015
Net income		$	14,773		$	21,469
Add back - Income tax expense			10,928			16,463
Income before income taxes			25,701			37,932
Adjustments:
Amortization of EnvisionRx intangible assets			20,853			17,040
LIFO charge			13,760			5,986
Loss on debt retirements, net			-			33,205
Merger and Acquisition-related costs			1,402			9,617
Adjusted income before income taxes			61,716			103,780
Adjusted income tax expense			26,229			45,041
Adjusted net income		$	35,487		$	58,739
Adjusted net income per diluted share:
Numerator for adjusted net income per diluted share:
Adjusted net income		$	35,487		$	58,739
Denominator:
Basic weighted average shares			1,044,198			1,029,793
Outstanding options and restricted shares, net			17,251			19,341
Diluted weighted average shares			1,061,449			1,049,134
Net income per diluted share		$	0.01		$	0.02
Adjusted net income per diluted share		$	0.03		$	0.06

RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
ADJUSTED NET INCOME
(Dollars in thousands, except per share amounts)
(unaudited)
		Twenty-six weeks ended August 27, 2016			Twenty-six weeks ended August 29, 2015
Net income		$	10,185		$	40,305
Add back - Income tax expense			4,619			28,904
Income before income taxes			14,804			69,209
Adjustments:
Amortization of EnvisionRx intangible assets			41,168			17,040
LIFO charge			27,511			11,973
Loss on debt retirements, net			-			33,205
Merger and Acquisition-related costs			4,158			11,701
Adjusted income before income taxes			87,641			143,128
Adjusted income tax expense			27,344			59,828
Adjusted net income		$	60,297		$	83,300
Adjusted net income per diluted share:
Numerator for adjusted net income per diluted share:
Adjusted net income		$	60,297		$	83,300
Denominator:
Basic weighted average shares			1,043,317			1,008,242
Outstanding options and restricted shares, net			17,210			18,959
Diluted weighted average shares			1,060,527			1,027,201
Net income per diluted share		$	0.01		$	0.04
Adjusted net income per diluted share		$	0.06		$	0.08

RITE AID CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands)
(unaudited)
		Thirteen weeks ended August 27, 2016				Thirteen weeks ended August 29, 2015
OPERATING ACTIVITIES:
Net income		$	14,773			$	21,469
Adjustments to reconcile to net cash used in operating activities:
Depreciation and amortization			142,051				127,699
Lease termination and impairment charges			7,233				9,637
LIFO charge			13,760				5,986
Loss on sale of assets, net			174				281
Stock-based compensation expense			12,552				8,831
Loss on debt retirements, net			-				33,205
Changes in deferred taxes			7,747				(7,966	)
Excess tax benefit on stock options and restricted stock			(2,365	)			(18,049	)
Changes in operating assets and liabilities:
Accounts receivable			(152,725	)			(2,908	)
Inventories			(216,911	)			(80,673	)
Accounts payable			34,693				(47,806	)
Other assets and liabilities, net			(8,060	)			(75,969	)
Net cash used in operating activities			(147,078	)			(26,263	)
INVESTING ACTIVITIES:
Payments for property, plant and equipment			(119,641	)			(130,646	)
Intangible assets acquired			(12,488	)			(29,169	)
Acquisition of businesses, net of cash acquired			-				(1,779,571	)
Proceeds from dispositions of assets and investments			3,745				3,243
Net cash used in investing activities			(128,384	)			(1,936,143	)
FINANCING ACTIVITIES:
Net proceeds from revolver			270,000				869,000
Principal payments on long-term debt			(5,509	)			(655,640	)
Change in zero balance cash accounts			(1,728	)			(17,034	)
Net proceeds from the issuance of common stock			1,587				4,727
Financing fees paid for early debt redemption			-				(26,003	)
Excess tax benefit on stock options and restricted stock			2,365				18,049
Deferred financing costs paid			-				(175	)
Net cash provided by financing activities			266,715				192,924
Decrease in cash and cash equivalents			(8,747	)			(1,769,482	)
Cash and cash equivalents, beginning of period			144,840				1,922,129
Cash and cash equivalents, end of period		$	136,093			$	152,647
SUPPLEMENTAL CASH FLOW INFORMATION
Payments for property, plant and equipment		$	119,641			$	130,646
Intangible assets acquired			12,488				29,169
Total cash capital expenditures			132,129				159,815
Equipment received for noncash consideration			114				1,466
Equipment financed under capital leases			1,307				471
Gross capital expenditures		$	133,550			$	161,752

RITE AID CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands)
(unaudited)
		Twenty-six weeks ended August 27, 2016				Twenty-six weeks ended August 29, 2015
OPERATING ACTIVITIES:
Net income		$	10,185			$	40,305
Adjustments to reconcile to net cash provided by operating activities:
Depreciation and amortization			280,839				237,348
Lease termination and impairment charges			13,014				14,659
LIFO charge			27,511				11,973
Loss on sale of assets, net			1,230				320
Stock-based compensation expense			23,696				16,201
Loss on debt retirements, net			-				33,205
Changes in deferred taxes			1,998				1,574
Excess tax benefit on stock options and restricted stock			(3,248	)			(20,869	)
Changes in operating assets and liabilities:
Accounts receivable			(227,255	)			8,119
Inventories			(157,471	)			(24,469	)
Accounts payable			150,339				31,909
Other assets and liabilities, net			(107,972	)			(8,703	)
Net cash provided by operating activities			12,866				341,572
INVESTING ACTIVITIES:
Payments for property, plant and equipment			(225,718	)			(271,683	)
Intangible assets acquired			(28,869	)			(43,462	)
Acquisition of businesses, net of cash acquired			-				(1,779,571	)
Proceeds from dispositions of assets and investments			6,833				6,081
Net cash used in investing activities			(247,754	)			(2,088,635	)
FINANCING ACTIVITIES:
Proceeds from issuance of long-term debt			-				1,800,000
Net proceeds from revolver			250,000				728,000
Principal payments on long-term debt			(11,230	)			(661,217	)
Change in zero balance cash accounts			534				(51,309	)
Net proceeds from the issuance of common stock			3,958				8,105
Financing fees paid for early debt redemption			-				(26,003	)
Excess tax benefit on stock options and restricted stock			3,248				20,869
Deferred financing costs paid			-				(34,634	)
Net cash provided by financing activities			246,510				1,783,811
Increase in cash and cash equivalents			11,622				36,748
Cash and cash equivalents, beginning of period			124,471				115,899
Cash and cash equivalents, end of period		$	136,093			$	152,647
SUPPLEMENTAL CASH FLOW INFORMATION
Payments for property, plant and equipment		$	225,718			$	271,683
Intangible assets acquired			28,869				43,462
Total cash capital expenditures			254,587				315,145
Equipment received for noncash consideration			746				2,011
Equipment financed under capital leases			2,860				1,271
Gross capital expenditures		$	258,193			$	318,427

View source version on businesswire.com: http://www.businesswire.com/news/home/20160922005525/en/